Resveratrol can enhance osteogenic differentiation and mitochondrial biogenesis from human periosteum-derived mesenchymal stem cells.
Mesenchymal stem cell
Mitochondria
Osteogenesis
Resveratrol
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
03 Jun 2020
03 Jun 2020
Historique:
received:
16
01
2020
accepted:
28
04
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
14
5
2021
Statut:
epublish
Résumé
Osteoporosis is a metabolic bone disorder that leads to low bone mass and microstructural deterioration of bone tissue and increases bone fractures. Resveratrol, a natural polyphenol compound, has pleiotropic effects including anti-oxidative, anti-aging, and anti-cancer effects. Resveratrol also has roles in increasing osteogenesis and in upregulating mitochondrial biogenesis of bone marrow-derived mesenchymal stem cells (BM-MSCs). However, it is still unclear that resveratrol can enhance osteogenic differentiation or mitochondrial biogenesis of periosteum-derived MSCs (PO-MSCs), which play key roles in bone tissue maintenance and fracture healing. Thus, in order to test a possible preventive or therapeutic effect of resveratrol on osteoporosis, this study investigated the effects of resveratrol treatments on osteogenic differentiation and mitochondrial biogenesis of PO-MSCs. The optimal doses of resveratrol treatment on PO-MSCs were determined by cell proliferation and viability assays. Osteogenic differentiation of PO-MSCs under resveratrol treatment was assessed by alkaline phosphatase activities (ALP, an early biomarker of osteogenesis) as well as by extracellular calcium deposit levels (a late biomarker). Mitochondrial biogenesis during osteogenic differentiation of PO-MSCs was measured by quantifying both mitochondrial mass and mitochondrial DNA (mtDNA) contents. Resveratrol treatments above 10 μM seem to have negative effects on cell proliferation and viability of PO-MSCs. Resveratrol treatment (at 5 μM) on PO-MSCs during osteogenic differentiation increased both ALP activities and calcium deposits compared to untreated control groups, demonstrating an enhancing effect of resveratrol on osteogenesis. In addition, resveratrol treatment (at 5 μM) during osteogenic differentiation of PO-MSCs increased both mitochondrial mass and mtDNA copy numbers, indicating that resveratrol can bolster mitochondrial biogenesis in the process of PO-MSC osteogenic differentiation. Taken together, the findings of this study describe the roles of resveratrol in promoting osteogenesis and mitochondrial biogenesis of human PO-MSCs suggesting a possible application of resveratrol as a supplement for osteoporosis and/or osteoporotic fractures.
Sections du résumé
BACKGROUND
BACKGROUND
Osteoporosis is a metabolic bone disorder that leads to low bone mass and microstructural deterioration of bone tissue and increases bone fractures. Resveratrol, a natural polyphenol compound, has pleiotropic effects including anti-oxidative, anti-aging, and anti-cancer effects. Resveratrol also has roles in increasing osteogenesis and in upregulating mitochondrial biogenesis of bone marrow-derived mesenchymal stem cells (BM-MSCs). However, it is still unclear that resveratrol can enhance osteogenic differentiation or mitochondrial biogenesis of periosteum-derived MSCs (PO-MSCs), which play key roles in bone tissue maintenance and fracture healing. Thus, in order to test a possible preventive or therapeutic effect of resveratrol on osteoporosis, this study investigated the effects of resveratrol treatments on osteogenic differentiation and mitochondrial biogenesis of PO-MSCs.
METHODS
METHODS
The optimal doses of resveratrol treatment on PO-MSCs were determined by cell proliferation and viability assays. Osteogenic differentiation of PO-MSCs under resveratrol treatment was assessed by alkaline phosphatase activities (ALP, an early biomarker of osteogenesis) as well as by extracellular calcium deposit levels (a late biomarker). Mitochondrial biogenesis during osteogenic differentiation of PO-MSCs was measured by quantifying both mitochondrial mass and mitochondrial DNA (mtDNA) contents.
RESULTS
RESULTS
Resveratrol treatments above 10 μM seem to have negative effects on cell proliferation and viability of PO-MSCs. Resveratrol treatment (at 5 μM) on PO-MSCs during osteogenic differentiation increased both ALP activities and calcium deposits compared to untreated control groups, demonstrating an enhancing effect of resveratrol on osteogenesis. In addition, resveratrol treatment (at 5 μM) during osteogenic differentiation of PO-MSCs increased both mitochondrial mass and mtDNA copy numbers, indicating that resveratrol can bolster mitochondrial biogenesis in the process of PO-MSC osteogenic differentiation.
CONCLUSION
CONCLUSIONS
Taken together, the findings of this study describe the roles of resveratrol in promoting osteogenesis and mitochondrial biogenesis of human PO-MSCs suggesting a possible application of resveratrol as a supplement for osteoporosis and/or osteoporotic fractures.
Identifiants
pubmed: 32493422
doi: 10.1186/s13018-020-01684-9
pii: 10.1186/s13018-020-01684-9
pmc: PMC7268497
doi:
Substances chimiques
Antioxidants
0
Resveratrol
Q369O8926L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
203Subventions
Organisme : National Research Foundation of Korea
ID : NRF-2019R1F1060013
Organisme : Gyeongsang National University Hospital of Korea (biomedical research institute fund)
ID : GNUHBIF-2015-0010
Références
Biofactors. 2018 Jan;44(1):69-82
pubmed: 29210129
Stem Cells Dev. 2016 Jan 15;25(2):114-22
pubmed: 26487485
Biomolecules. 2019 May 30;9(6):
pubmed: 31151226
Clin Orthop Relat Res. 2007 May;458:175-9
pubmed: 17224836
J Agric Food Chem. 2002 May 22;50(11):3337-40
pubmed: 12010007
Biofactors. 2018 Jan;44(1):36-49
pubmed: 29193412
Transfus Med Hemother. 2016 Jul;43(4):256-267
pubmed: 27721701
J Cell Biochem. 2019 Oct;120(10):16634-16642
pubmed: 31106448
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
Nutr Diabetes. 2018 Sep 20;8(1):51
pubmed: 30237505
Stem Cells Int. 2017;2017:2638305
pubmed: 28698718
N Engl J Med. 2006 Jul 13;355(2):125-37
pubmed: 16837676
Obstet Gynecol. 2004 Oct;104(4):837-44
pubmed: 15458908
Monoclon Antib Immunodiagn Immunother. 2020 Apr;39(2):29-36
pubmed: 32195618
J Bone Joint Surg Br. 2006 Oct;88(10):1272-8
pubmed: 17012413
Nestle Nutr Inst Workshop Ser. 2015;83:71-81
pubmed: 26484873
J Bone Miner Res. 2015 Jan;30(1):3-23
pubmed: 25414052
Cytotherapy. 2014 Dec;16(12):1643-55
pubmed: 25231892
PLoS One. 2012;7(4):e35160
pubmed: 22523573
Phytomedicine. 2016 Dec 15;23(14):1787-1796
pubmed: 27912881
Best Pract Res Clin Rheumatol. 2006 Aug;20(4):695-706
pubmed: 16979533
Oxid Med Cell Longev. 2016;2016:6705621
pubmed: 26770656
Arthritis Rheum. 2006 Apr;54(4):1209-21
pubmed: 16575900
Plast Reconstr Surg. 1998 Mar;101(3):567-74; discussion 575-6
pubmed: 9500373
J Bone Miner Res. 2009 Feb;24(2):274-82
pubmed: 18847330
J Transl Med. 2014 Jan 07;12:8
pubmed: 24397850
Antioxid Redox Signal. 2014 Jun 1;20(16):2589-605
pubmed: 24041027
Toxicol Pathol. 2002 May-Jun;30(3):312-21
pubmed: 12051548
J Tissue Eng Regen Med. 2012 Dec;6 Suppl 3:s34-46
pubmed: 22467433
J Agric Food Chem. 2014 Nov 12;62(45):10928-35
pubmed: 25360711
Br J Pharmacol. 2013 Oct;170(4):796-806
pubmed: 23848300
Biochim Biophys Acta. 2014 Jul;1842(7):902-15
pubmed: 24582596
Biomaterials. 2014 Aug;35(26):7326-35
pubmed: 24933514
Nat Commun. 2018 Feb 22;9(1):773
pubmed: 29472541
Acta Orthop. 2015 Feb;86(1):100-7
pubmed: 25582459
Injury. 2007 Mar;38 Suppl 1:S90-9
pubmed: 17383490
PLoS One. 2011;6(6):e20914
pubmed: 21698063
Exp Ther Med. 2018 Jan;15(1):576-584
pubmed: 29387206
Osteoporos Int. 2005 Mar;16 Suppl 2:S3-7
pubmed: 15365697
Nat Rev Mol Cell Biol. 2014 Apr;15(4):243-56
pubmed: 24651542
Clin Orthop Surg. 2018 Sep;10(3):271-278
pubmed: 30174801
Mol Pain. 2016 Nov 11;12:
pubmed: 27837171
Calcif Tissue Int. 2010 Oct;87(4):298-304
pubmed: 20803291
Stem Cells Dev. 2012 Mar 1;21(4):575-88
pubmed: 21615273
Stem Cells. 2008 Apr;26(4):960-8
pubmed: 18218821
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Crit Rev Food Sci Nutr. 2014;54(6):734-70
pubmed: 24345046
Clin Orthop Surg. 2018 Sep;10(3):389-392
pubmed: 30174818
Cells Tissues Organs. 2017;204(2):59-83
pubmed: 28647733
Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H13-20
pubmed: 19429820
PLoS One. 2012;7(4):e35712
pubmed: 22539994
Arthritis Rheum. 2001 Jan;44(1):85-95
pubmed: 11212180
J Cell Physiol. 2011 Oct;226(10):2562-70
pubmed: 21792913
Exp Cell Res. 2009 Oct 15;315(17):2953-62
pubmed: 19665018
Mutat Res Genet Toxicol Environ Mutagen. 2018 Jan;825:19-30
pubmed: 29307372
Mol Nutr Food Res. 2017 May;61(5):
pubmed: 27958670
Metabolism. 2012 Jul;61(7):954-65
pubmed: 22209670
NIH Consens Statement. 2000 Mar 27-29;17(1):1-45
pubmed: 11525451
Front Nutr. 2016 Apr 12;3:8
pubmed: 27148534
PLoS One. 2012;7(5):e37162
pubmed: 22615926
Arch Pharm Res. 2019 Dec;42(12):1052-1062
pubmed: 31802425
J Popul Ther Clin Pharmacol. 2020 Jan 06;27(1):e25-e31
pubmed: 31922699
Eur Cell Mater. 2016 May 24;31:341-54
pubmed: 27215741
Biochemistry (Mosc). 2019 Jun;84(6):686-692
pubmed: 31238868
Nutr Cancer. 2017 Oct;69(7):1019-1027
pubmed: 28937798
PLoS One. 2013 Oct 18;8(10):e77077
pubmed: 24204740